The Joint Federal Committee (G-BA) has passed a resolution on the evaluation of the appropriate comparator therapy for Voxelotor (Oxbryta, Global Blood Therapeutics Germany GmbH) for the treatment of hemolytic anaemia due to sickle cell disease as monotherapy or in combination with hydroxycarbamide in adults, children and adolescents from the age of 12 years:
Voxelotor is approved as a medicinal product for the treatment of rare disease, thus the added benefit is considered proven by the approval.
There is a indication of a non-quantifiable added benefit, because the scientific data basis does not allow quantification.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/g-ba-nutzenbewertung-f%25C3%25BCr-voxelotor-2022a10027w7